Figure 2
From: Smurf2 inhibition enhances chemotherapy and radiation sensitivity in non-small-cell lung cancer
Clonogenic survival analysis and Smurf2 expression in bortezomib-treated PC9 and A549 cells. Western blot analysis showed that 20 nM bortezomib reduced Smurf2 protein expression in PC9 and A549 cells (A). Combined treatment with bortezomib (20 nM) plus cisplatin and bortezomib (20 nM) plus radiation in PC9 and A549 cells significantly decreased clonogenic survival compared to that of the corresponding cells treated with cisplatin and radiation alone, respectively (B). Overexpression of Smurf2 with two separate targeting plasmid constructs in A549 cells (Smurf2 OE 1, 2) compared to wild-type expression of Smurf2 in control A549 cells (nontargeting control). Overexpression of Smurf2 rescued A549 cells from the toxic effects of radiation and bortezomib treatment, as evaluated by clonogenic assays (C).
